Saturday 17 October 2026
Export TRIB’s income statement to Excel — free account
Trinity Biotech PLC
TRIB Healthcare Medical Devices
Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
8.03
0.10
+1.26%
Follow TRIB
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.22 | 0.33 | 0.40 | 0.24 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.79) | (9.94) | 140.45 | (7.09) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.09 | 3.31 | 2.77 | 2.48 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(34.53) | (24.41) | (122.17) | (25.18) | |
EV/FCF |
(11.77) | (10.28) | (12.05) | (7.57) | |
Quick Ratio |
0.09 | 0.12 | 0.46 | 0.39 | |
Current Ratio |
0.22 | 0.25 | 1.03 | 1.05 | |
Net Debt/EBITDA |
(69.19) | (30.59) | (970.26) | (37.52) | |
Debt/Assets |
134.49% | 128.55% | 110.75% | 110.46% | |
Debt/Equity |
(1.81) | (1.88) | (2.10) | (2.22) | |
Asset Turnover |
0.47 | 0.42 | 0.48 | 0.51 | |
Operating CF/Net income |
0.26 | 0.08 | (0.03) | 0.29 | |
Capex/Depreciation |
(0.06) | (1.10) | (2.23) | (5.92) | |
Interest Coverage |
(1.51) | (0.39) | (0.18) | (1.67) | |
Research and Development Expense of Revenue |
8.47% | 9.56% | 5.71% | 5.88% | |
Selling, General and Administrative Expense of Revenue |
51.48% | 69.26% | 45.12% | 69.48% | |
Intangible Assets out of Total Assets |
0.58 | 0.54 | 0.56 | 0.56 | |
Share Based Compensation of Revenue |
0.15% | 0.33% | 0.44% | 0.87% | |
Graham Net Nets |
(14.31) | (9.63) | (6.34) | (9.60) | |
Graham Number |
374.50 | 394.57 | 374.78 | 370.20 | |
Earnings Yield |
(320.72%) | (250.90%) | (227.16%) | (391.18%) | |
Free Cash Flow Yield |
(120.70%) | (96.02%) | (57.70%) | (133.68%) | |
Revenue per Share |
17.18 | 17.90 | 23.04 | 17.46 | |
Operating CF per Share |
(1.84) | (2.38) | 0.22 | (2.75) | |
Capex per Share |
(0.07) | (1.30) | (2.37) | (6.27) | |
Free Cash Flow per Share |
(1.91) | (3.68) | (2.15) | (9.02) | |
Cash per Share |
3.20 | 8.31 | 2.16 | 2.49 | |
Shareholders Equity per Share |
(119.97) | (116.36) | (88.08) | (79.85) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(119.97) | (116.36) | (88.08) | (79.85) | |
Free Cash Flow |
(1.20) | (2.28) | (1.33) | (5.60) | |
Working Capital |
(112.32) | (105.31) | 1.02 | 1.48 | |
Capital Expenditures |
(0.04) | (0.80) | (1.47) | (3.89) | |
Net Current Asset Value |
(146.28) | (141.24) | (122.91) | (116.17) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.07 | 0.10 | 0.36 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.56 | 13.77 | 17.85 | 14.18 | |
Average Payables |
27.57 | 28.24 | 27.83 | 24.78 | |
Average Inventory |
19.27 | 19.10 | 20.48 | 21.54 | |
Average Assets |
100.85 | 104.23 | 100.58 | 96.99 | |
Average Common Equity |
(59.68) | (53.58) | (40.53) | (39.47) |
Columns are period end dates